Insider Buying: Amarillo Biosciences Inc (AMAR) Insider Acquires 533,334 Shares of Stock

Amarillo Biosciences Inc (OTCMKTS:AMAR) insider Stephen T. Chen purchased 533,334 shares of the company’s stock in a transaction dated Thursday, November 1st. The shares were acquired at an average price of $0.21 per share, with a total value of $112,000.14. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of AMAR traded up $0.05 during trading hours on Tuesday, reaching $0.56. 1,000 shares of the company’s stock traded hands, compared to its average volume of 6,661. Amarillo Biosciences Inc has a 12 month low of $0.15 and a 12 month high of $0.61.

Amarillo Biosciences (OTCMKTS:AMAR) last issued its quarterly earnings results on Monday, August 13th. The company reported ($0.01) earnings per share (EPS) for the quarter.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/11/06/insider-buying-amarillo-biosciences-inc-amar-insider-acquires-533334-shares-of-stock.html.

About Amarillo Biosciences

Amarillo Biosciences, Inc engages in the development of biologics for the treatment of human and animal diseases. The company owns or licenses five issued patents related to the low-dose oral delivery of interferon; and owns one issued patent on its dietary supplement, Maxisal. It focuses on research for the treatment of human disease indications primarily influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha.

Further Reading: What are the Benefits of Index Funds?

Insider Buying and Selling by Quarter for Amarillo Biosciences (OTCMKTS:AMAR)

Receive News & Ratings for Amarillo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarillo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply